Abstract 974P
Background
The burgeoning demand for hepatectomy in elderly patients with hepatocellular carcinoma (HCC) necessitates improved perioperative care. Geriatric populations frequently experience functional decline and frailty, predisposing them to adverse postoperative outcomes. The Barthel Index serves as a reliable measure for assessing functional capacity, and this study evaluates its impact on surgical textbook outcomes (TOs) as composite quality indicators following hepatectomy in elderly HCC patients.
Methods
A multicenter retrospective cohort study analyzed elderly patients (≥70 years) who underwent hepatectomy for HCC between 2013 and 2021 at 11 Chinese hospitals. Utilizing a Barthel Index cut-off value of 85, patients were divided into two groups: with and without preoperative functional decline and frailty. The primary outcome was TO, encompassing seven criteria. TO rates were compared between groups, and multivariate logistic regression analyses identified independent risk factors for achieving TOs.
Results
Of 497 elderly HCC patients, 157 (31.6%) exhibited preoperative functional decline and frailty (Barthel Index score <85). The overall TO rate was 58.6%. Patients with preoperative Barthel Index score <85 had significantly lower TO rates compared to patients with preoperative Barthel Index score ≥85 (29.3% vs. 72.1%, P<0.001). Similar differences emerged regarding perioperative blood transfusion, postoperative major morbidity, prolonged hospital stays, 30-day readmission, and 90-day mortality rates. Multivariate analysis revealed preoperative Barthel Index score <85 as an independent risk for achieving TO (odds ratio 3.413, 95% confidence interval 1.879-6.198, P<0.001). Comparable results were observed in subgroup population of patients undergoing open and laparoscopic hepatectomy, respectively.
Conclusions
Preoperative Barthel Index-based assessment of functional decline and frailty significantly predicts TOs following hepatectomy in elderly HCC patients, enabling identification of high-risk patients and informing preoperative management and postoperative care within geriatric oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China; Dawn Project Foundation of Shanghai; Shanghai Health Academic Leader Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18